文献速递肝病消化道肿瘤与早癌

比较肝硬化患者肝细胞癌预测概率与一般人群:改善风险沟通的契机?

Comparing Predicted Probability of Hepatocellular Carcinoma in Patients With Cirrhosis With the General Population: An Opportunity to Improve Risk Communication?
PubMed 文献 · Am J Gastroenterol · 2022-06-24

该研究纳入苏格兰2018年4月前达到持续病毒学应答的肝硬化患者1803例,用aMAP模型预测3年肝细胞癌概率,并与一般人群按人口学分层的3年发生率比较。肝硬化患者平均预测3年概率为3.64%(范围0.012%-36.12%),一般人群为<0.0001%至0.25%;平均发生率比为410,平均绝对风险差为3.61%。作者认为将个体预测概率与一般人群比较可行,可能有助于风险沟通和筛查依从。

要点

  • 肝硬化持续病毒学应答患者平均预测3年肝细胞癌概率为3.64%,范围0.012%-36.12%。
  • 一般人群3年肝细胞癌概率为<0.0001%至0.25%,平均发生率比为410。
  • 平均绝对风险差为3.61%,范围0.012%-35.9%。

核心结论

  • 将患者预测肝细胞癌概率与一般人群比较是可行的,可能有助于临床医生沟通风险信息并促进筛查接受。

研究设计与样本

  • 纳入苏格兰2018年4月前达到持续病毒学应答的肝硬化患者共1803例,使用aMAP预后模型预测持续病毒学应答时的3年肝细胞癌概率。
  • 一般人群肝细胞癌 Incidence 数据来自苏格兰公共卫生局,按人口学特征分层。
  • 采用发生率比和绝对风险差两种指标比较肝硬化患者预测风险与一般人群风险。

主要发现

  • 肝硬化持续病毒学应答患者平均预测3年肝细胞癌概率为3.64%(范围0.012%-36.12%)。
  • 一般人群3年肝细胞癌概率远低于肝硬化患者,为<0.0001%至0.25%,因人口学特征而异。
  • 平均发生率比为410,范围5至>10,000。
  • 平均绝对风险差为3.61%,范围0.012%-35.9%。

关键数值与推荐

  • 在线肝细胞癌与一般人群比较计算器可供患者和临床医生使用,网址为https://thrive-svr.shinyapps.io/RShiny/。

临床怎么用

  • 作者认为将患者预测肝细胞癌概率与一般人群比较可能有助于临床医生沟通风险信息并促进筛查接受。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Risk scores estimating a patient's probability of a hepatocellular carcinoma (HCC) diagnosis are abundant but are difficult to interpret in isolation. We compared the predicted HCC probability for individuals with cirrhosis and cured hepatitis C with the general population (GP). METHODS: All patients with cirrhosis achieving sustained viral response (SVR) in Scotland by April 2018 were included (N = 1,803). The predicted 3-year probability of HCC at time of SVR achievement was determined using the aMAP prognostic model. GP data on the total number of incident HCCs in Scotland, stratified by demographics, were obtained from Public Health Scotland. Predicted HCC risk of cirrhosis SVR patients was compared with GP incidence using 2 metrics: (i) incidence ratio: i.e., 3-year predicted probability for a given patient divided by the 3-year probability in GP for the equivalent demographic group and (ii) absolute risk difference: the 3-year predicted probability minus the 3-year probability in the GP. RESULTS: The mean predicted 3-year HCC probability among cirrhosis SVR patients was 3.64% (range: 0.012%-36.12%). Conversely, the 3-year HCC probability in the GP was much lower, ranging from <0.0001% to 0.25% depending on demographics. The mean incidence ratio was 410, ranging from 5 to >10,000. The mean absolute risk difference was 3.61%, ranging from 0.012% to 35.9%. An online HCC-GP comparison calculator for use by patients/clinicians is available at https://thrive-svr.shinyapps.io/RShiny/ . DISCUSSION: Comparing a patient's predicted HCC probability with the GP is feasible and may help clinicians communicate risk information and encourage screening uptake.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Innes H, Hamill V, McDonald SA, et al. Comparing Predicted Probability of Hepatocellular Carcinoma in Patients With Cirrhosis With the General Population: An Opportunity to Improve Risk Communication? Am J Gastroenterol. 2022. PMID: 35973177. doi:10.14309/ajg.0000000000001879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。